Invention Grant
US09381176B2 E-prostanoid receptor, Ptger3, as a novel anti-diabetic therapeutic target
有权
E-前列腺素受体，Ptger3，作为新型抗糖尿病治疗靶点
- Patent Title: E-prostanoid receptor, Ptger3, as a novel anti-diabetic therapeutic target
- Patent Title (中): E-前列腺素受体，Ptger3，作为新型抗糖尿病治疗靶点
-
Application No.: US13774516Application Date: 2013-02-22
-
Publication No.: US09381176B2Publication Date: 2016-07-05
- Inventor: Mark Keller , Alan Attie , Michelle Kimple
- Applicant: Wisconsin Alumni Research Foundation
- Applicant Address: US WI Madison
- Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
- Current Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
- Current Assignee Address: US WI Madison
- Agency: Quarles & Brady LLP
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61K8/28 ; A61K38/26 ; A61P5/50 ; A61P3/08 ; A61P3/10 ; A61P7/12 ; C07K14/605 ; A61K31/18 ; A61K31/404 ; A61K31/4985
Abstract:
Provided herein are methods for increasing insulin secretion from beta cells. Also provide herein are methods comprising administering to a subject in need of increased insulin secretion a composition comprising a compound that directly or indirectly activates adenylate cyclase and an E prostanoid 3 (EP3) receptor antagonist that attenuates G alpha-i-subfamily (GSIS)-mediated adenylate cyclase inhibition.
Public/Granted literature
- US20130244932A1 E-PROSTANOID RECEPTOR, PTGER3, AS A NOVEL ANTI-DIABETIC THERAPEUTIC TARGET Public/Granted day:2013-09-19
Information query
IPC分类:
